[石榴皮衍生的细胞外纳米纤维的抗糖尿病活性成分]
Yu-Fang Bi1, Yun-Hong Huang2, Tao Yuan2
1School of Health, Jiangxi Normal University Nanchang 330022, China College of Chemistry and Chemical Engineering, Jiangxi Normal University Nanchang 330022, China.
概括
来自石榴皮的细胞外纳米微粒通过抑制α-葡萄糖酶和改善胰岛素耐药性,表现出强大的抗糖尿病活性. 这些纳米微粒为糖尿病管理提供了有前途的自然疗法.
科学领域:
- 生物技术是生物技术.
- 纳米医学是一种纳米医学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病是一种全球性健康问题,具有显著的发病率.
- 目前的治疗方法有局限性,需要新的治疗策略.
- 自然产品为开发新的抗糖尿病药物提供了丰富的来源.
研究的目的:
- 为了分离和描述石榴皮衍生的细胞外纳米纤维 (PPENs).
- 为了在体外评估PPENs的抗糖尿病潜力.
- 阐明PPEN活动背后的分子组件和机制.
主要方法:
- 使用超高速离心和糖密度梯度离心隔离了PPEN.
- PPENs的形态和结构特征.
- 试验室试验包括HepG2细胞中的α-葡萄糖酶抑制和胰岛素抵抗模型.
- 脂质组,蛋白质组,代谢物和miRNA测序使用染色体质谱学进行.
主要成果:
- PPENs显示出显著的α-葡萄糖酶抑制 (IC50 = 35.3 μg·mL-1),超过了阿卡尔.
- PPENs在100μg·mL-1.1时增强了胰岛素抵抗HepG2细胞的葡萄糖吸收.
- 分析显示,PPEN中含有丰富的脂质和运输蛋白.
- 凯格路径分析表明脂质和miRNAs是关键活性成分.
结论:
- PPENs具有显著的抗糖尿病特性.
- PPENs的脂质和miRNA含量可能会调解它们的治疗效果.
- PPENs代表了糖尿病治疗的有前途的天然纳米疗法.
更多相关视频
07:03Isolation, Characterization, and Therapeutic Application of Extracellular Vesicles from Cultured Human Mesenchymal Stem Cells
Published on: September 23, 2022
2.0K
09:31Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
Published on: November 5, 2016
7.2K
相关概念视频
01:05Insulin Secretory Vesicles
4.9K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
4.9K
01:24Glucagon-like Receptor Agonists
311
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
311